The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index; none of the 31 sources its claims cite is checked for support yet.
Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent
Open accessAbstract
Background: Honey exhibits a broad spectrum of antibacterial activity against Gram‐positive and Gram‐negative bacteria, including methicillin‐resistant Staphylococcus aureus (MRSA) ones. Chitosan (Cs) is a mucoadhesive polymer that also has antibacterial properties. Special attention has been paid to the design of polymeric nanoparticles (NPs) as new nano drug delivery systems to overcome bacterial resistance and its problems. Objectives: The aim of the present study is to synthesize Cs‐meropenem NPs with/without honey as an antibiofilm and antibacterial agent to inhibit Staphylococcus aureus . Methods: This study synthesized meropenem and honey‐loaded Cs nanogels and subsequently characterized them by Field Emission Scanning Electron Microscopy (FESEM), Fourier Transform Infrared Spectroscopy (FTIR), and DLS‐zeta potential. Using the broth microdilution and crystal violet assays, the antibacterial and antibiofilm activity of meropenem and honey‐loaded Cs nanogel, free meropenem, free honey, and free Cs NPs were investigated in vitro against MRSA strains. 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl‐2H‐tetrazolium bromide (MTT) was also used to test the cytotoxicity of several Cs‐NPs compound against the HEK‐293 regular cell line. Results: The average size of meropenem and honey‐Cs‐NPs was reported to be 119.885 nm, and encapsulation efficiency was 88.33 ± 0.97 with stability up to 60 days at 4°C. The NPs showed enhanced antibiofilm efficacy against S. aureus at sub‐minimum inhibitory concentrations. Additionally, the cytotoxicity of meropenem and honey‐encapsulated Cs against the HEK‐293 normal cell line was insignificant. Conclusions: Our findings suggested that meropenem and honey‐Cs‐NPs might be potential antibacterial and antibiofilm materials.
Overview
CoChat Summary
TL;DR
Meropenem and honey co-encapsulated in chitosan nanoparticles (C6) showed enhanced in vitro antibacterial/antibiofilm activity against multidrug-resistant, biofilm-forming *Staphylococcus aureus* and improved survival in a murine sepsis model. The formulation had high encapsulation efficiency, sustained release, and low cytotoxicity toward HEK-293 cells.
Key findings
- The optimized C6 formulation (Cs + meropenem + honey) had a FESEM size of 119.885 nm, hydrodynamic diameter 266.2 ± 0.28 nm, PDI 0.118 ± 0.004, zeta potential +48.0 ± 1 mV, and encapsulation efficiency 88.33 ± 0.97%, with stability up to 60 days at 4°C.
- Among 300 clinical samples, 106 (35.33%) were MRSA, 93/106 (87.73%) were MDR, 66/93 (70.96%) were vancomycin-resistant, and all 93 MDR isolates produced biofilm. C6 showed MIC 0.125–0.5 µg/mL, MBC 0.25–1.0 µg/mL, and MBIC 0.062–0.25 µg/mL across four selected strains, lower than free meropenem (MIC 2–4, MBC 4–8, MBIC 2–4 µg/mL).
- C6 significantly reduced expression of biofilm-associated genes *ompA*, *pgaB*, and *Bap* (p < 0.00001) and was minimally toxic to HEK-293 cells at 256 µM (cell survival >70%), whereas free meropenem was toxic at 256 µM.
- In a murine *S. aureus* sepsis model, C6-treated mice had 87.5% survival versus 12.5% for free meropenem, 50% for Cs + meropenem, and 0% for free Cs.
Methods
- Chitosan nanoparticles with meropenem and/or honey were prepared in combinations C1–C6 and characterized by FESEM, FTIR, DLS/zeta potential, encapsulation efficiency, and in vitro release at pH 3.0, 5.0, and 7.4.
- *S. aureus* was isolated from 300 patients (175 women, 125 men, average age 42 years) in Shahrekord hospitals during 2021–2022; susceptibility was tested by disk diffusion (CLSI), biofilm by Congo red/microtiter assays, MIC/MBC by broth microdilution, MBIC by crystal violet, biofilm gene expression by qRT-PCR, and cytotoxicity by MTT on HEK-293 cells.
- In vivo, 42 female BALB/c mice (20–25 g, 6–8 weeks) were infected intraperitoneally with *S. aureus* (10⁷ CFU/mL) twice 2 weeks apart, divided into seven groups (six mice/cage), and treated with C1–C6 or control; survival, body weight, and clinical score were assessed.
Limitations
- The paper states that chitosan has limited solubility in water and most organic solvents, restricting applicability, and that chitosan nanoparticles have constraints including cytotoxicity, degradability, and poor mechanical qualities; it also notes that further trials are required for effective field applications.
- Evident from the text: in vitro antibacterial, antibiofilm, and gene-expression assays used only four selected clinical isolates plus ATCC 33592; the in vivo study used 42 mice (6/group) with short observation, and no pharmacokinetic, long-term toxicity, or mechanistic data are reported.
- Evident from the text: some reported values are inconsistent, e.g., FESEM size 119.885 nm versus DLS hydrodynamic diameter 266.2 nm, and release described as 38% at 6 h and 60% within 120 h alongside 82%/72% initial burst in the first hour.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
0 Valid · 2 Not valid · 31 Not checked · 85 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The findings of the vancomycin screen agar revealed that among 93 MDR isolates, 66 isolates (70.96%) were vancomycin‐resistant.”
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > RESULTS > Screening of resistant bacteria collected from sources
plainn = 93- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“According to the findings, treatment with a different combination of Cs‐encapsulated meropenem caused the most significant decrease in the expression of genes ompA, pgaB, and Bap (p ≤ 0.05).”
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > RESULTS > Meropenem‐honey Cs‐NPs reduce the transcription of biofilm‐associated genes
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, among the various combinations, the C6 combination showed the best efficiency (***p < 0.00001).”
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > RESULTS > Meropenem‐honey Cs‐NPs reduce the transcription of biofilm‐associated genes
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, free meropenem demonstrated toxicity at a dosage of 256 µM (Figure 6).”
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > RESULTS > MTT assay
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared to free meropenem, the C6 combination significantly reduced the quantity of biofilm by 28 times the MBIC in all of the samples studied.”
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > RESULTS > Antibacterial and antibiofilm activity of meropenem‐honey Cs NPs
plainstates a causen = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
64 more claims
Create a free account to see all 118 claims and to verify the 26 references still open.
- It may state two separate claims as one. 37
- Probably not a substantial claim. 20
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > DISCUSSION
“However, the antibiofilm efficacy was significantly increased when both were encapsulated with Cs.”
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > RESULTS > Antibacterial and antibiofilm activity of meropenem‐honey Cs NPs
“| Sample 7 | Strong | 8 | 8 | 4 | 4 | 4 | 2 | 4 | 8 | 2 | C4 | 0.25 | 0.50 | 0.125 | | Sample 7 | Strong | 8 | 8 | 4 | 4 | 4 | 2 | 4 | 8 | 2 | C5 | 1.0 | 2.0 | 0.50 | | Sample 7 | Strong | 8 | 8 | 4 | 4 | 4 | 2 | 4 | 8 | 2 | C6 | 0.5 | 1.0 | 0.25 |”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > RESULTS > Bactericidal effects of prepared NPs in vivo
“| C6 | 19.4 ± 0.2 | 0 | 18.2 ± 0.31 | 0 | 87.5 a |”
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > MATERIALS AND METHODS > Analysis of cytotoxicity in vivo
“After induced chronic infection, the animals were randomly divided into seven groups (six mice/cage).”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“| | Emam Ali = 34 (32.07%) | 30 (88.23%) | VA, CIP, CD, AK | 9 | 17 | 30 | Strong | 16 | + | + | + |”
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > RESULTS > Screening of resistant bacteria collected from sources
Reported 17 · recomputed 30
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > RESULTS > Bactericidal effects of prepared NPs in vivo
“all animals treated with meropenem and honey‐loaded NPs dispersions survived for 48 h”
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > RESULTS > Bactericidal effects of prepared NPs in vivo
“| C6 | 19.4 ± 0.2 | 0 | 18.2 ± 0.31 | 0 | 87.5 a |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > RESULTS > Characterization of NPs
“| Meropenem + Cs | 0.179 ±1.001 | +45 ± 0.5 | 70.12 | 277.5 ± 0.75 | 66.16 ± 5.04 |”
§ Fabrication and antimicrobial properties of novel meropenem‐honey encapsulated chitosan nanoparticles against multiresistant and biofilm‐forming Staphylococcus aureus as a new antimicrobial agent > DISCUSSION
“The PDI is a number that ranges from 0 to 1.”
1 more finding
Create a free account to see every finding of this check.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“10.1007/s12010-023-04709-1”
Cited work 10.1007/s12010-023-04709-1 · retracted 2023-09-01 · notice 10.1007/s12010-023-04709-1 · this paper published 2024-04-13
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Ghourchian, H., Pecho, R. D., Karimi‐Dehkordi, M., Mazandarani, A., Ghajari, G., & Piri‐Gharaghie, T. (2023). Novel niosome‐encapsulated 2, 5‐diketopiperazine (BHPPD): Synthesis, formulation, and anti‐breast cancer activity. Applied Biochemistry and Biotechnology,,. 10.1007/s12010-023-04687-4 37624507”
Cited work 10.1007/s12010-023-04687-4 · retracted 2026-09-03 · notice 10.1007/s12010-026-05907-3 · this paper published 2024-04-13
Citations
Cites
2 retracted
Ghourchian, H., Pecho, R. D. C., Karimi-Dehkordi, M., Mazandarani, A., Ghajari, G., & Piri-Gharaghie, T. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04687-4 · Cited by 15
RetractedGhajari, G., Naser, R. H., Pecho, R. D. C., Alhili, F., & Piri-Gharaghie, T. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04709-1 · Cited by 10
RetractedAntibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Preparation and antibacterial activity of chitosan nanoparticles
Qi, L., Xu, Z., Jiang, X., Hu, C., & Zou, X. (2004) · Carbohydrate Research · doi:10.1016/j.carres.2004.09.007 · Cited by 1,804
Bacterial biofilm formation on implantable devices and approaches to its treatment and prevention
Khatoon, Z., McTiernan, C. D., Suuronen, E. J., Mah, T.-F., & Alarcon, E. I. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e01067 · Cited by 1,187
Multidrug-Resistant Bacteria in the Community
van Duin, D., & Paterson, D. L. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.02.004 · Cited by 584
A Survey of the Antibacterial Activity of Some New Zealand Honeys
Allen, K. L., Molan, P. C., & Reid, G. M. (1991) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1991.tb03186.x · Cited by 571
Bacterial resistance to antibiotics: Active efflux and reduced uptake
KUMAR, A., & SCHWEIZER, H. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.04.004 · Cited by 529
Study of the in vitro cytotoxicity testing of medical devices
LI, W., ZHOU, J., & XU, Y. (2015) · Biomedical Reports · doi:10.3892/br.2015.481 · Cited by 461
Challenges of intervention, treatment, and antibiotic resistance of biofilm-forming microorganisms
Gebreyohannes, G., Nyerere, A., Bii, C., & Sbhatu, D. B. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02192 · Cited by 414
Research works printed but not linked: 2
- CLSI, 2020, Performance standards for antimicrobial susceptibility testing; twenty‐second informational supplement (
- Riss T. L., 2004, Assay guidance manual [internet], 146
Cited by
Anisha, S., & Sathishkumar, P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.137850 · Cited by 19
Mengesha, Y. (2025) · Discover Nano · doi:10.1186/s11671-025-04244-4 · Cited by 15
Chitosan-based structures for targeting bacterial biofilm-associated genes
Afrasiabi, S. (2025) · Carbohydrate Polymer Technologies and Applications · doi:10.1016/j.carpta.2025.101077 · Cited by 9
Espinel, P. S., Spencer, L. M., Alberício, F., & Rodríguez, H. (2025) · Applied Sciences · doi:10.3390/app151810103 · Cited by 5
Zhang, Y., & Zhang, C. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04923-0 · Cited by 4
Metadata
- Authors
- Hajimohammadi, S., Momtaz, H., & Tajbakhsh, E.
- Affiliations
- Islamic Azad University of Shahrekord (IR)
- Corresponding author
- Momtaz, Hassan
- Venue
- Veterinary Medicine and Science
- Publisher
- Wiley
- Published
- 2024-04-13
- Volume
- 10
- Issue
- 3
- Pages
- e1440-e1440
- ISSN
- 2053-1095 (ISSN-L)
- PMC
- PMC11015535
- OpenAlex
- W4394784240
- Semantic Scholar
- ee2ced55cd5b1e67955283929692104f26c2a3db
- Cited by
- 12
- References
- 52
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 2
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Veterinary Medicine and Science (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Islamic Azad University, Shahrekord
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Materials Chemistry › Nanoparticles: synthesis and applications
- Keywords
- meropenem, honey, chitosan nanoparticles, nanogels, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, biofilm inhibition, antibacterial activity, multidrug resistance, drug delivery systems, encapsulation efficiency, cytotoxicity, HEK293 cells
- MeSH terms
- Meropenem, Animals, Anti-Infective Agents, Anti-Bacterial Agents, Gram-Negative Bacteria, Gram-Positive Bacteria, Honey, Humans, Staphylococcal Infections, Staphylococcus aureus, Biofilms, Chitosan, Nanoparticles, Methicillin-Resistant Staphylococcus aureus, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.